Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | MAP3K8 | P41279 | 3/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | F9 | P00740 | 3/20 | 0.35 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26193975 | 0.88 | ALOX5 (0.41) | LIMK1PIK3CAPI4KAPI4KBMAP3K8 | |
| SCHEMBL25817967 | 0.88 | ESR1 (0.35) | ESR1ESR2LIMK1PIK3CAPI4KA | |
| SCHEMBL22240839 | 0.87 | MEN1 (0.41) | LIMK1PIK3CAPI4KAPI4KBF9 | |
| SCHEMBL25817895 | 0.87 | ALDH1A1 (0.37) | ESR1ESR2LIMK1PIK3CAPI4KA | |
| SCHEMBL25817727 | 0.87 | F9 (0.35) | ESR1ESR2LIMK1PIK3CAPI4KA | |
| SCHEMBL23027546 | 0.87 | F9 (0.40) | LIMK1PIK3CAPI4KAPI4KBMAP3K8 | |
| SCHEMBL23027553 | 0.87 | F9 (0.40) | LIMK1PIK3CAPI4KAPI4KBMAP3K8 | |
| SCHEMBL25817720 | 0.87 | ESR1 (0.39) | ESR1ESR2LIMK1PIK3CAPI4KA | |
| SCHEMBL25818448 | 0.87 | ESR1 (0.39) | ESR1ESR2LIMK1PIK3CAPI4KA | |
| SCHEMBL22240893 | 0.86 | PIK3CA (0.45) | LIMK1PIK3CAPI4KAPI4KBF9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917914-B1 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11917914-B1 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230225206-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230225206-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | DUK SAN NEOLUX CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11917914-B1 | Compound for organic electronic element, organic electronic element using the same, and an electronic device thereof | NFE2L2, ESR1, OR51E2 | ESR1 2/4885ESR2 14/4885LIMK1 905/4885 |
| US-20230225206-A1 | COMPOUND FOR ORGANIC ELECTRONIC ELEMENT, ORGANIC ELECTRONIC ELEMENT USING THE SAME, AND AN ELECTRONIC DEVICE THEREOF | NFE2L2, ESR1, OR51E2 | ESR1 2/4885ESR2 14/4885LIMK1 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.